Jarushka Naidoo, Consultant Medical Oncologist at Beaumont Hospital and Full Professor at Royal College of Surgeons in Ireland, shared a post on X:
“Interesting translational synthesis on RB1-proficient SCLC, a distinct biologic entity:
- constitutes ~5–10% of SCLCs
- non-NE, YAP1 features
- potential vulnerability to CDK4/6i in preclinical models.”
Title: Retinoblastoma Proficient Small Cell Carcinoma: A Novel Entity with Therapeutic Vulnerability?
Authors: Afshin Dowlati, Reza Ferdousi, Abhishek Ajay, Cammie Brewster, Brandon J. Grubb, Angelina Golya, Omid Savari, Minh Lam, Gary M. Wildey
Read the Full Article.
Serum CEA May Reflect Tumor Biology Across Molecular Subtypes in Metastatic NSCLC